Bpifrance

Shippeo Secures $32M Investment From Battery Ventures and Existing Investors, Bringing Total Funds Raised to $71M Since Launch

Thursday, January 14, 2021 - 7:00am

This new round is co-led by Battery Ventures, a global, technology focused investment firm and existing investors (NGP Capital, ETF Partners, Partech and Bpifrance Digital Venture).

Key Points: 
  • This new round is co-led by Battery Ventures, a global, technology focused investment firm and existing investors (NGP Capital, ETF Partners, Partech and Bpifrance Digital Venture).
  • Shippeo will use the investment to strengthen its market-leading position and continue delivering on product innovation.
  • The Covid-19 crisis has highlighted the need for supply-chain visibility, with major shippers across industries needing enhanced transparency more than ever before.
  • Last October, Shippeo acquired the French company oPhone, bringing major customers in the retail and manufacturing sectors into its community.

Jeito Capital becomes major investor in SparingVision as part of €44.5 Million financing

Wednesday, October 21, 2020 - 6:00am

Paris, France, 21 October 2020 Jeito Capital (Jeito), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has become a major investor in SparingVision, a French preclinical stage biotech company focused on gene therapy in ophthalmology.

Key Points: 
  • Paris, France, 21 October 2020 Jeito Capital (Jeito), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has become a major investor in SparingVision, a French preclinical stage biotech company focused on gene therapy in ophthalmology.
  • The 44.5 million financing round brought together new investors alongside Jeito including 4BIO Capital, University of Pittsburgh Medical Center Enterprise and Ysios Capital; along with further investment from current holders, Bpifrance and Foundation Fighting Blindness.
  • SparingVision becomes Jeitos first French, and second European, after Neogene Therapeutics, investment following Jeitos fund I launch in January 2020.
  • SparingVisions investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital.

Carbios Acquires Limagrain Ingredients’ Entire Stake in the Capital of Carbiolice

Thursday, October 8, 2020 - 5:41pm

The acquisition of Limagrain Ingredients shareholding in Carbiolice is consistent with our desire to strengthen value creation for our shareholders.

Key Points: 
  • The acquisition of Limagrain Ingredients shareholding in Carbiolice is consistent with our desire to strengthen value creation for our shareholders.
  • For example, a shareholder holding 1% on the Carbios share capital prior to the Offering will now have a 0.99% stake.
  • Prior to the Offering, Carbios and Limagrain Ingredients held respectively 52.70% and 18.02% of Carbiolices share capital.
  • As such, Carbios created the joint venture Carbiolice in September 2016, in partnership with Limagrain Ingredients and the SPI fund operated by Bpifrance.

Pixium Vision notified of threshold crossing following passive dilution

Monday, September 28, 2020 - 6:00am

Paris, 28 September 2020 7:00 am CET Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, has been informed by Bpifrance Investissement of a passive crossing of the threshold of 5% of the share capital, following the increase in the total number of shares and voting rights of the Company due to the conversion by L1 Capital of an amount of convertible debt into shares.

Key Points: 
  • Paris, 28 September 2020 7:00 am CET Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, has been informed by Bpifrance Investissement of a passive crossing of the threshold of 5% of the share capital, following the increase in the total number of shares and voting rights of the Company due to the conversion by L1 Capital of an amount of convertible debt into shares.
  • Bpifrance has not sold any shares and continues to support Pixium Vision and its strategy, through its active and continuing presence on its Board of Directors as well as through its holding of 6,150,344 shares since July 2020.
  • Bpifrance Investissement holds 2,134,094 shares since September 25th, 2020, representing 4,99% of the share capital at the date of this press release.

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020

Friday, July 17, 2020 - 5:20pm

Nanobiotixs revenue for the second quarter 2020 and for the first half of 2020 amounted to 13.4k and 36.9k respectively.

Key Points: 
  • Nanobiotixs revenue for the second quarter 2020 and for the first half of 2020 amounted to 13.4k and 36.9k respectively.
  • The second PGE of 5m granted by Bpifrance has been received on July 17, 2020.
  • In April 2020, the Company provided updates on clinical development continuity in the context of the COVID-19 crisis.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix.

INGENICO GROUP: Worldline filed its proposed tender offer for Ingenico securities with the Autorité des marchés financiers (AMF) - Ingenico's board of directors issued a favorable reasoned opinion on the offer

Wednesday, July 8, 2020 - 7:25am

Today, we have achieved an important step in the creation of the new European World-Class leader in digital payments.

Key Points: 
  • Today, we have achieved an important step in the creation of the new European World-Class leader in digital payments.
  • It is recalled that Bpifrance Participations has also undertaken to tender its Ingenico shares, representing 5.31% of Ingenico's capital, to the tender offer.
  • Worldline's draft offer document and Ingenico's reply offer document are available on the AMF website ( www.amf-france.org ), as well as on the websites of Worldline ( www.fr.worldline.com ) and Ingenico ( www.ingenico.com ).
  • The tender offer and the draft offer document remain subject to review by the AMF, which will assess their compliance with applicable laws and regulations.

Insuretech Tinubu Square Raises €15M Capital Investments

Thursday, February 13, 2020 - 8:00am

Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces an additional investment of 15M by New York-based Long Arc Capital and the French investment bank Bpifrance.

Key Points: 
  • Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces an additional investment of 15M by New York-based Long Arc Capital and the French investment bank Bpifrance.
  • Tinubu Square intends to use the additional 15M of capital to target high growth international markets for Credit Insurance and Surety software.
  • At the end of 2017, Long Arc Capital and Bpifrance invested 53M in Tinubu Square.
  • The Tinubu team has performed incredibly well over the last few years, said Vincent Fleury, Tinubu Board Member and a Partner of Long Arc Capital.

Groupe PSA and FCA agree to merge

Wednesday, December 18, 2019 - 6:45am

New entity will have the leadership, resources and scale to be at the forefront of a new era of sustainable mobility

Key Points: 
  • New entity will have the leadership, resources and scale to be at the forefront of a new era of sustainable mobility
    Creates a diversified business with among the highest margins in its core markets of Europe, North America and Latin America and the opportunity to reshape the strategy in other regions
    Combined company will leverage investment efficiency across a larger scale to develop innovative mobility solutions and cutting edge technologies in new energy vehicles, autonomous driving and connectivity
    Excellent working relationship between the two management teams, which share successful track records in turnarounds, value creation and successful OEM combinations
    Strong governance structure to underpin combined company performance with John Elkann as Group Chairman and Carlos Tavares as Group CEO, with a majority of independent directors2
    Strong support of long-term shareholders (EXOR N.V., Peugeot Family Group, Bpifrance) who will be represented on the Board

Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Tuesday, September 3, 2019 - 12:00pm

The company and its collaborators will deliver presentations on its lead drug enmetazobactam (formerly AAI101), a potent extended-spectrum -lactamase (ESBL) inhibitor.

Key Points: 
  • The company and its collaborators will deliver presentations on its lead drug enmetazobactam (formerly AAI101), a potent extended-spectrum -lactamase (ESBL) inhibitor.
  • We are excited to share data from four posters at ASM/ESCMID this year.
  • Allecra is supported by Forbion, Delos Capital, Andera Partners, formerly EdRIP, Xeraya Capital, EMBL Ventures, and BioMed Partners.
  • Allecras wholly owned French subsidiary is a beneficiary of financial support from the French public bank Bpifrance and from the Rgion Alsace.

Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme

Wednesday, March 13, 2019 - 4:45pm

Under the agreement, the NEOVIVA project will receive 5.2 million over the five-year duration of the program from Bpifrance, of which Transgene will receive 2.6 million.

Key Points: 
  • Under the agreement, the NEOVIVA project will receive 5.2 million over the five-year duration of the program from Bpifrance, of which Transgene will receive 2.6 million.
  • We would like to thank Bpifrance for its financial support which will accelerate the development of myvac.
  • We are delighted to have access to our partners expertise through the NEOVIVA project, said Philippe Archinard, CEO and Chairman of Transgene.
  • We expect this project to further boost the development of Transgene bioproduction manufacturing unit for this individualized immunotherapy.